You are here: Industry Insights > Novartis

News List

Novartis expands development programs for NASH with Allergan clinical partnership europeanpharmaceuticalreview
April 21, 2017
Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH).
Novartis’ lymphoma treatment receives FDA breakthrough therapy designation europeanpharmaceuticalreview
April 20, 2017
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy...
Allergan and Novartis join forces to develop NASH combo therapy pharmafile
April 19, 2017
Allergan and Novartis have announced a new partnership to conduct a clinical trial in the treatment area of non-alcoholic steatohepatitis (NASH), evaluating two of their treatments as a combination therapy.
Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Ad drugs.com
April 19, 2017
Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019...
Allergan and Novartis in Clinical Collaboration contractpharma
April 19, 2017
Will evaluate use of Allergan's cenicriviroc and Novartis lead FXR agonist to treat NASH
Novartis Collaborates With Allergan On NASH - Quick Facts nasdaq
April 18, 2017
(RTTNews.com) - Novartis ( NVS ) said that it has entered into a clinical trial agreement with Allergan plc to conduct a Phase IIb study, involving the combination of a Novartis FXR agonist and Allergan's cenicriviroc or CVC for the treatment of non-alcoh
India's Torrent Pharma inks deal with Novartis biospectrumasia
April 14, 2017
The closure of the deal is subject to the approval of Competition Commission of India ('CCI') and other applicable regulatory approvals
Novartis takes home rights to Lubris’ eye drug pharmatimes
April 10, 2017
Novartis has elected to exercise an option to in-license experimental eye drug ECF843 from US biopharma Lubris.
Novartis to in-licence ECF843 for ophthalmic indications globally pharmaceutical-technology
April 10, 2017
Swiss pharmaceutical company Novartis has exercised an option to in-licence ECF843 for ophthalmic indications across worldwide (outside Europe), as part of efforts to strengthen its R&D pipeline
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications cphi-online
April 10, 2017
ECF843 is a new therapeutic approach and potential first-in-class Rx treatment in dry-eye.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page